The bill amends Section 5030.1 of the Oklahoma Statutes regarding the Medicaid Drug Utilization Review Board, which is established within the Oklahoma Health Care Authority. The amendments modify the appointment procedures for board members, specifying that the board will consist of ten members, including four physicians, four licensed pharmacists, one lay community representative, and one pharmaceutical industry representative. Notably, the number of physician candidates submitted by the Oklahoma State Medical Association has been reduced from six to three, and the term limits for board members have been clarified, allowing for a maximum of three three-year terms and one partial term.

Additionally, the bill updates statutory language, including changing "vice-chair" to "vice chair" and replacing "Pharmaceutical" with "Pharmacists" in the association's name. The bill also emphasizes the importance of geographic balance in member representation and outlines the procedures for filling vacancies. The Medicaid Drug Utilization Review Board is tasked with advising the Oklahoma Health Care Authority on drug utilization programs and must comply with the Oklahoma Open Meeting Act and the Administrative Procedures Act. The act is set to take effect on November 1, 2025.